Haas et al. monitored Th17-cell frequency in MS patients without, during and after NAT cessation and found increased frequencies in the immunology periphery during long term treatment as well as a decrease after NAT withdrawal. The gene discussed is BRD2; the disease is myeloid sarcoma.